Investment Rating - The report maintains a "Positive" investment rating for the healthcare sector [11] Core Insights - The innovative chain sector is entering a new growth cycle driven by both domestic and international demand, with significant improvements expected in China's innovative drug R&D investment starting in 2025 [2][6] - Chinese innovative drug companies are expected to see a substantial increase in available funds, with a projected total of 201.5 billion yuan in IPO fundraising and financing activities in 2025, marking a 145% year-on-year increase [6] - The report highlights the strong performance of CDMO companies, with significant order improvements anticipated by mid-2024, and a positive trend in their financial performance [7] - The innovative drug sector is entering a realization phase with low valuation levels, and numerous catalysts expected in Q2 2026, suggesting a favorable outlook for investments in this area [8] Summary by Sections Domestic Demand - By 2025, the investment climate for innovative drug R&D in China is expected to improve, leading to a new cycle of prosperity in the innovative drug industry [6] - The funding available to Chinese pharmaceutical companies is increasing, with a projected 880.5 billion yuan in potential milestone payments from external business development (BD) activities, a 185.9% year-on-year increase [6] International Demand - CDMO companies focused on overseas revenue are expected to see significant improvements in new orders starting from Q2 2024, with year-on-year growth rates recovering to over 15% [7] - WuXi AppTec's backlog is projected to reach 58 billion yuan by the end of 2025, reflecting a 28.8% year-on-year increase, with expected revenue growth of 18-22% in 2026 [7] Innovative Drug Sector - The innovative drug sector is entering a realization phase with low valuations, supported by a series of policy measures that have been implemented since 2024 [8] - The number of Chinese companies participating in international academic conferences is increasing, with over 100 expected to present nearly 400 research outcomes in 2026 [8] Technological Advancements - Chinese pharmaceutical companies are rapidly enhancing their global competitiveness, with innovative technologies such as second-generation ADCs and molecular therapies being developed at a leading global level [9] - The report suggests that the outbound business development strategies are diversifying, including mergers and collaborations, which could enhance the global presence of Chinese pharmaceutical companies [9]

Core Viewpoint - The company, Zhaoyan New Drug (06127.HK), reported significant growth in its 2025 annual performance, with a revenue of RMB 1.658 billion and a net profit attributable to shareholders of RMB 299 million, reflecting a substantial year-on-year increase of 302.1% [1] Group 1: Financial Performance - In 2025, the company achieved a revenue of RMB 1.658 billion and a net profit of RMB 299 million, marking a year-on-year growth of 302.1% [1] - The company proposed a final dividend of RMB 0.12 per ordinary share [1] Group 2: Industry Context - The domestic biopharmaceutical industry maintained stable investment and financing activity in 2025, showing signs of recovery [1] Group 3: Business Development - The company focused on enhancing market expansion and technological empowerment, driving growth across all business lines [1] - The total order amount on hand was approximately RMB 2.6 billion, with new signed orders also around RMB 2.6 billion [1] Group 4: Quality and Innovation - The company emphasized maintaining business quality and operational standards, ensuring data authenticity and accuracy [2] - Continuous professional training and capability enhancement for personnel were conducted to ensure the scientific and uniform quality of projects [2] - The company is committed to technological innovation to meet the evolving research and development needs, thereby solidifying its leading position in the industry [2] - Project management processes and quality management systems were further optimized to enhance customer satisfaction and support business growth [2]

Core Viewpoint - The innovative drug sector has reached a stage where it is largely ignored by the market, despite positive changes in company fundamentals and a significant increase in the number of licensing deals [3][4][5]. Group 1: Historical Context of the Innovative Drug Sector - The current market cycle for innovative drugs has transitioned from a period of significant valuation decline to a recovery phase, with many companies' valuations hitting historical lows [6][7]. - A clear turning point in fundamentals was observed in early 2025, with a shift from a model reliant on continuous funding for R&D to one focused on revenue generation from product sales and improved cash flow [7]. - The number of licensing deals in China surged to approximately 157, with a total value exceeding $130 billion, more than doubling from the previous year, indicating a strong presence in the global business development market [7][8]. Group 2: Recent Market Adjustments - From September 2025 to February 2026, many companies experienced a market correction of around 30%, primarily driven by funding issues and external market conditions rather than fundamental industry problems [9][10]. - The disconnect between industry progress and stock price performance is evident, with the sector experiencing a typical "good industry + temporary negative sentiment" scenario [11]. Group 3: Comparison with Previous Market Cycles - The current phase (2025 onwards) differs significantly from the previous cycle (2018-2020), which was characterized by domestic institutional benefits and valuation discovery, with many companies still in early clinical stages [12][13]. - In contrast, the current cycle features companies that have advanced to leading positions in certain therapeutic areas, with a notable increase in the global market share of Chinese innovative drugs [13][14]. Group 4: Future Outlook for 2026 - The year 2026 is anticipated to be pivotal, with a shift from speculative valuations to a focus on actual data and cash flow, as companies like BeiGene are expected to achieve significant profitability [15][16]. - Key clinical milestones for several major drugs are expected in 2026, which will serve as critical tests for their global market potential [17][18]. Group 5: Market Trends and Opportunities - The global innovative drug market is projected to grow at a compound annual growth rate (CAGR) approaching double digits, potentially exceeding $1 trillion by 2030, with the Chinese market expected to reach approximately $100 billion by 2025 [21][22]. - The role of Chinese innovative drugs in the global supply chain is evolving from a passive participant to a significant contributor, with increasing procurement from multinational pharmaceutical companies [22][23]. Group 6: Catalysts for Market Recovery - The market is currently in a phase of adjustment, with a need for a catalyst to realign value perceptions, which could come from significant clinical data releases at major conferences or a shift in investor focus back to innovative drugs [24][25]. - The emergence of a landmark drug achieving global market entry and pricing could significantly uplift the sector's overall valuation [26].

Core Viewpoint - The pharmaceutical sector, characterized by both technology and consumer attributes, is expected to continue exhibiting structural trends amid market fluctuations, with a focus on innovative drug segments and emerging technologies like AI in healthcare [1][2]. Group 1: Market Performance - The Shanghai and Shenzhen 300 index rose by 0.36%, while the pharmaceutical and biological sector declined by 0.81%, ranking 21st among 31 primary sub-industries [2][4]. - The medical services sector increased by 0.22%, while chemical pharmaceuticals, biological products, medical devices, traditional Chinese medicine, and pharmaceutical commerce saw declines of 0.54%, 0.89%, 1.07%, 1.75%, and 2.68% respectively [2][4]. Group 2: Investment Recommendations - Companies are advised to focus on sectors with positive fundamental changes and light institutional holdings, particularly in the AI healthcare and small nucleic acid segments, which have shown strong performance [2][3]. - The report suggests monitoring companies that are not primarily in the pharmaceutical/medical AI+ sector but are actively adopting related technologies with potential for short-term valuation flexibility [2]. Group 3: In Vivo CAR Developments - Multiple clinical studies for in vivo CAR are expected to reach major endpoints within the year, particularly those targeting autoimmune indications, indicating significant potential for this cutting-edge technology [3][4]. - Abbvie's acquisition of Capstan for $21 billion is highlighted, with its core pipeline expected to reach major clinical endpoints soon, focusing on safety and immune response indicators, which could pave the way for further development in autoimmune indications [4]. Group 4: Overall Sector Analysis - The pharmaceutical sector has yielded a return of 2.44% since early 2026, outperforming the Shanghai and Shenzhen 300 index by 1.79 percentage points [4].

Summary of Conference Call for Reborio Biotech Company and Industry - **Company**: Reborio Biotech (瑞博生物) - **Industry**: MASH (Metabolic Associated Steatotic Hepatitis) treatment and small nucleic acid therapeutics Key Points and Arguments 1. **Collaboration with Madrigal**: Reborio has entered into a business development agreement with Madrigal (MDGL), which includes a $60 million upfront payment and potential milestones totaling $4.3 billion. This partnership is seen as mutually beneficial, particularly in the large market for MASH indications [1] 2. **Reborio's Expertise**: Reborio possesses significant experience in transitioning from preclinical to clinical stages, which aligns well with the clinical requirements outlined by MDGL. This capability allows Reborio to accurately determine preclinical data needs, facilitating the collaboration [1] 3. **Madrigal's Position**: Madrigal is recognized as a pioneer in the MASH field, with its product Rezdiffra being a daily oral treatment. The acquisition of Pfizer's DGAT2 has positioned Madrigal favorably, with no other companies currently entering the MASH space [2] 4. **Combination of Therapies**: The collaboration aims to combine Madrigal's short-acting small molecules with Reborio's long-acting small nucleic acids, creating a synergistic treatment approach [2] 5. **Unmet Clinical Needs**: There is a significant unmet clinical need in MASH, as existing drug mechanisms are too generic. Current treatments primarily reduce liver fat, indirectly addressing disease impact without targeting disease characteristics, fibrosis, or specific genotypes and subtypes [2] 6. **Reborio's Focus**: Although Reborio has excellent preclinical data for MASH, it is not the primary focus of the company’s clinical strategy. The optimal solution is to pursue licensing agreements rather than direct clinical development [2] 7. **Pipeline Diversity**: The collaboration encompasses six distinct pipelines that offer complementary mechanisms, indicating a strategic approach to diversifying treatment options [2] 8. **Future Milestones**: Within the next two years, Reborio aims to achieve at least one Investigational New Drug (IND) application for MASH or generate significant revenue [2] 9. **Collaboration with Boehringer Ingelheim (BI)**: Reborio's collaboration with BI focuses on different targets and indications compared to MDGL, with BI emphasizing late-stage liver disease and complications, aiming for scientific breakthroughs in first-in-class (FIC) innovations [2] 10. **Progress and Milestones**: Current progress aligns with expectations, having already achieved two milestones, with the anticipated timeline for the MDGL collaboration pipeline to enter IND status concurrently [2] 11. **Innovative Technologies**: Reborio is leading globally in kidney-targeted therapies and has early-stage assets for liver-external delivery, as well as dual-target approaches [2]

Core Viewpoint - The report from交银国际 indicates a slight decrease in the proportion of domestic investors holding pharmaceutical stocks through the Hong Kong Stock Connect since the fourth quarter of last year, while foreign investment has increased, particularly in innovative drugs and leading CXO companies benefiting from demand recovery [1] Group 1: Investment Trends - Domestic investors' holdings in pharmaceutical stocks via Hong Kong Stock Connect have slightly decreased [1] - Foreign investors have increased their positions, particularly in innovative drug companies and leading CXO firms [1] Group 2: Investment Recommendations - The report suggests focusing on differentiated platforms such as small nucleic acids, long-acting formulations, invivo CAR-T, and new generation ADC/XDC, as well as disease areas like autoimmune, metabolic, and CNS [1] - The pharmaceutical sector is expected to maintain a stable upward trend this year, although short-term volatility may occur [1] Group 3: Stock Selection Criteria - Investors are advised to examine company fundamentals and valuations to identify undervalued stocks, such as 三生制药, 和黄医药, and 劲方医药, which have rich catalysts not yet reflected in their valuations [1] - CXO segment leaders, like 药明合联, are expected to benefit from a favorable downstream environment and improved financing conditions [1] - Sub-sectors such as hospitals, medical devices, and diagnostics are anticipated to see regulatory uncertainties gradually easing along with positive policy expectations [1]

Group 1: Gold and Silver Market Outlook - A Reuters survey indicates that gold prices are expected to reach a new high of $4,746.50 per ounce by 2026, driven by geopolitical uncertainties and strong central bank purchases, marking a significant increase from last year's forecast of $4,275 [1] - The average price expectation for silver in 2026 has also been raised to $79.50 per ounce, up from $50 in the previous year's survey [1] Group 2: Currency and Economic Analysis - The strong US dollar is exerting downward pressure on gold and silver prices, with analysts suggesting that if the dollar's rebound continues, it may further impact gold prices negatively [2] - UBS forecasts a 10% increase in global stock markets by the end of the year, with a focus on diversification into markets like China, Japan, and Europe, driven by strategic autonomy and fiscal expansion [3] - Mitsubishi UFJ reports that the Japanese yen has fallen to a near two-week low due to election expectations, with potential for continued selling pressure as confidence in the ruling party's stability grows [4] - Goldman Sachs warns of upward fiscal risks in Japan ahead of the upcoming elections, suggesting that unless the Bank of Japan accelerates interest rate hikes, the yen may weaken further [6] Group 3: Sector-Specific Insights - Zhongtai Securities expresses a positive outlook on the raw material pharmaceutical sector, highlighting innovations in small nucleic acids and ADC toxins as catalysts for growth [7] - CITIC Securities recommends focusing on automotive companies with strong cost transfer capabilities and global layouts, as rising raw material prices are expected to pressure profit margins in the first quarter of 2026 [8] - Galaxy Securities identifies two main paths for AI-driven benefits: enhancing platform efficiency and improving production efficiency through content and tools, suggesting a focus on internet stocks and AI-related applications [9]

Group 1 - Current U.S. financial market conditions do not support the initiation of balance sheet reduction, as liquidity pressures have only recently eased and reserve levels remain limited [1] - The Federal Reserve's asset holdings are approximately 20% of GDP, nearing pre-pandemic levels, indicating a constrained liquidity environment [1] - If the proposed balance sheet reduction is implemented quickly under a new Federal Reserve chair, it may lead to renewed liquidity pressures in the U.S. financial markets [1] Group 2 - The supply-demand situation for traditional electronic fabrics, particularly the 7628 electronic fabric, is expected to remain tight through 2026, with price increases likely exceeding market expectations [2] - Prices for 7628 electronic fabric could reach over 6 yuan per meter, indicating significant upward price potential [2] Group 3 - The raw material pharmaceutical sector is strategically favored, with innovative drug segments such as small nucleic acids, peptides, and ADC toxins driving continuous industry chain catalysts [3] - Many companies in the sector are at a turning point, with existing business stabilizing and new business opportunities expected to emerge [3] - Following several years of price declines, the raw material and intermediate industry is anticipated to see price improvements due to rising commodity and upstream chemical prices [3]

Core Viewpoint - The chemical raw material pharmaceutical industry is experiencing a prolonged downturn, but leading companies are expected to transition from cyclical stocks to innovative industry chains, driven by rising upstream costs, policy-driven market clearing, and the maturation of new drug trends such as GLP-1 oral small molecules and small nucleic acids [1][2][3][4]. Group 1: Industry Challenges - The chemical raw material pharmaceutical PPI index has been under long-term pressure, with various product prices, including sartans, heparins, and animal health products, dropping to historical lows, leading some leading companies to report losses [2]. - The price reduction effects from centralized procurement are gradually impacting upstream raw materials, resulting in declining profit margins for raw material pharmaceuticals [2]. Group 2: Growth Opportunities - Rising raw material prices and exchange rates, along with anti-involution policies, are expected to accelerate market clearing in the raw material pharmaceutical industry, allowing companies to potentially initiate a second growth curve [3]. - The upcoming industrial transformation in 2026 for GLP-1 oral small molecules and small nucleic acid drugs is anticipated to generate significant global demand for APIs and intermediates, establishing a trend that favors companies positioned within the MNC supply chain [4]. Group 3: Investment Recommendations - Companies that are positioned within the MNC supply chain, such as Chengda Pharmaceutical, Lianhua Technology, WuXi AppTec, and others, are recommended for investment as they are likely to benefit from the transition to an innovative industry chain [4].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas deal for its long-acting peptide drug metabolism AI discovery platform, involving an upfront payment of USD 1.2 billion, potential R&D milestone payments of up to USD 3.5 billion, and sales milestone payments of up to USD 13.8 billion, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is noted as the largest deal in the domestic pharmaceutical sector for the year, comparable to a previous major deal between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a projected rapid year-on-year growth in net profit for 2026 [1]. - The long-acting metabolism platform is considered rare globally, with only Camurus having a similar platform, which enhances the company's competitive position in the overseas weight loss market [2]. Summary by Sections Transaction Details - The deal with AstraZeneca includes an upfront payment of USD 1.2 billion, potential R&D milestones of up to USD 3.5 billion, and sales milestones of up to USD 13.8 billion, along with a royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R and three preclinical weight loss pipelines, with plans for collaboration on four additional projects [2]. Platform Mechanism - The company possesses a leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company has a robust pipeline including EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The ADC pipeline targets HER3, B7H3, DLL3, and aims to address gaps in lung squamous carcinoma treatment [3]. Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are estimated at RMB 4.45 billion, RMB 8.46 billion, and RMB 5.60 billion respectively, with corresponding EPS of RMB 0.39, RMB 0.73, and RMB 0.49 [4][9]. - The company is assigned a PE ratio of 24 times for 2026, with a target price adjustment reflecting market conditions [4][11].